Platelet Volume Is Reduced In Metastasing Breast Cancer: Blood Profiles Reveal Significant Shifts

Figures & data

Table 1 Baseline Characteristics Of BC Patients

Variables	With Liver Metastases	Without Liver Metastases	P value
N	211	215
Age (years)	52.9 (8.8)	50.4 (9.8)	0.006
BMI (kg/m^2)	23.4 (3.4)	24.2 (3.0)	0.007
Menopausal status
(Post, %)	138 (65.4)	134 (62.3)	0.234
FPG (mmol/L)	5.20 (4.90– 5.83)	5.20 (4.90– 5.60)	0.205
Albumin (g/L)	44.0 (5.3)	45.0 (5.3)	0.063
Creatinine (umol/L)	68.0 (18.3)	71.2 (15.6)	0.053
WBC (×10^9/L)	6.2 (2.1)	6.1 (1.8)	0.423
Haemoglobin (g/dL)	124.8 (16.1)	134.6 (12.2)	<0.001
Platelet count (×10^9/L)	239.7 (81.2)	235.5 (51.8)	0.524
MPV (fL)	8.2 (1.4)	9.1 (1.2)	<0.001
PDW (%)	16.9 (1.5)	16.8 (1.0)	0.137
Lactate dehydrogenase (U/L)	200.0(157.2–286.0)	153.0(138.0–172.0)	<0.001
CEA (ng/mL)	12.8 (2.7–59.7)	1.3 (0.9–2.0)	<0.001
CA153 (U/mL)	81.7 (25.3–287.0)	9.8 (7.3–13.4)	<0.001
ER (Positive, %)	119 (56.4)	138 (64.2)	0.100
PR (Positive, %)	115 (54.5)	135 (62.8)	0.082
HER-2 status (Positive, %)	76 (36.0)	92 (42.8)	0.153
Tumor molecular subtype
Luminal-A	121 (57.3)	107 (49.8)	0.117
Luminal-B	49 (23.2)	46 (21.4)	0.651
HER 2+	20 (9.5)	32 (14.9)	0.088
TNBC	21 (10.0)	30 (14.0)	0.203

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; WBC, white blood cell; MPV, mean platelet volume; PDW, platelet distribution width; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.

Table 2 Platelet Indices In BC Patients

Variables	PLT(×10^9/L)	P value	MPV(fL)	P value	PDW(%)	P value
Without liver metastases
Tumor T stage		0.544		0.985		0.136
T1+T2	235.0 (51.3)		9.1 (1.2)		16.7 (1.0)
T3+T4	245.2 (64.4)		9.1 (1.3)		17.2 (0.7)
Tumor N stage		0.321		0.115		0.046
N0	234.3 (50.8)		9.1 (1.1)		16.7 (1.0)
N1–3	246.1 (60.8)		8.7 (1.5)		17.2 (0.7)
Tumor Size		0.811		0.781		0.198
<2.5 cm	235.0 (50.9)		9.1 (1.1)		16.7 (1.0)
≥2.5 cm	237.1 (55.9)		9.0 (1.6)		16.9 (1.1)
With liver metastases
Liver Tumor Nodules		0.975		0.390		0.700
<2	239.8 (85.5)		8.4 (1.3)		16.9 (1.6)
≥2	239.8 (85.5)		8.2 (1.4)		17.0 (1.4)
Liver Tumor Size		0.385		0.052		0.069
≤50 mm	241.8 (80.7)		8.1 (1.3)		16.9 (1.5)
>50 mm	228.6 (84.0)		8.6 (1.6)		17.4 (1.2)
Extrahepatic Involvement		0.558		0.168		0.853
Liver only involved	241.0 (82.7)		8.2 (1.4)		16.9 (1.5)
Liver + other sites^a	231.3 (70.8)		8.6 (1.6)		17.0 (1.3)

Note: ^alung, bone, and brain.

Abbreviations: BMI, body mass index; PLT, platelet count; MPV, mean platelet volume; PDW, platelet distribution width.

Figure 1 The prevalence rate of liver metastases (%) in BC patients according to MPV quartiles.

Notes: Figure 1 shows the association between MPV levels and prevalence rate of liver metastases in BC patients (%). Participants were stratified into quartiles according to their MPV levels. The prevalence of liver metastases is calculated by the quartiles of MPV levels.

Table 3 The Risks Of Liver Metastases In BC Patients According To MPV Quartiles

	Cases	Controls	OR (95% CI)	p-value
Q1 (≤7.8 fL)	93	20	1 (reference)
Q2 (7.9–8.5 fL)	52	51	0.267 (0.134–0.530)	<0.001
Q3 (8.6–9.4 fL)	30	81	0.072 (0.034–0.152)	<0.001
Q4 (≥9.5 fL)	36	63	0.137 (0.066–0.281)	<0.001

Note: Logistic regression analysis adjusted for age.

Abbreviations: BMI, menopausal status; FPG, albumin, haemoglobin, creatinine, and WBC; CI, confidence interval.